MediFit Weight Loss

MediFit Weight Loss operates as a specialized metabolic health clinic in San Diego, California, focusing exclusively on physician-supervised weight management through peptide therapy and comprehensive lifestyle modification. The clinic's approach centers on GLP-1 receptor agonist medications combined with structured behavioral support, distinguishing itself from general wellness centers through its singular focus on sustainable weight reduction and metabolic optimization. Patients receive in-person consultations at the San Diego facility, where medical providers conduct thorough metabolic assessments including body composition analysis, hormonal panels, and cardiovascular risk stratification before initiating treatment protocols.

The clinic's peptide therapy program features two primary medications: semaglutide and tirzepatide, both administered via subcutaneous injection on weekly schedules. Semaglutide dosing typically begins at 0.25 mg weekly with gradual titration to therapeutic levels between 1.0-2.4 mg based on individual response and tolerance. Tirzepatide protocols start at 2.5 mg weekly, with potential escalation to 5 mg, 7.5 mg, 10 mg, or 15 mg depending on weight loss trajectory and metabolic markers. MediFit Weight Loss maintains a partnership with a compounding pharmacy that provides these peptides with verified potency testing, ensuring medication quality and consistent dosing accuracy. The clinic's medical team adjusts peptide protocols based on regular monitoring of thyroid function, glucose metabolism, and lipid profiles throughout treatment.

The San Diego clinic implements a structured check-in system where patients maintain regular contact with medical staff between monthly in-person visits. This accountability framework addresses the behavioral components of weight management, with providers reviewing food logs, activity patterns, and adherence challenges during these touchpoints. The medical team educates patients on the physiological mechanisms of GLP-1 agonists, including appetite regulation through hypothalamic signaling and delayed gastric emptying, enabling informed participation in treatment decisions. Providers at MediFit Weight Loss also address hormonal factors that influence weight regulation, including thyroid optimization, cortisol management, and sex hormone balance when laboratory findings indicate endocrine contributions to metabolic dysfunction.

Patients beginning treatment at the San Diego location undergo an initial consultation that includes medical history review, current medication assessment, and discussion of previous weight loss attempts to identify patterns and obstacles. The clinic's providers establish baseline measurements including weight, body mass index, waist circumference, blood pressure, and when indicated, hemoglobin A1c and fasting insulin levels. Treatment plans incorporate specific nutritional guidance tailored to GLP-1 therapy, addressing common challenges such as adequate protein intake, hydration management, and strategies to minimize gastrointestinal side effects during dose escalation phases. The clinic provides patients with injection technique training and supplies, ensuring proper administration and storage of peptide medications.

MediFit Weight Loss differentiates its San Diego practice through its emphasis on habit formation and lifestyle integration rather than temporary dietary restriction. The medical team works with patients to identify sustainable eating patterns, movement routines, and stress management techniques that support long-term weight maintenance beyond the active peptide therapy phase. The clinic's approach recognizes that GLP-1 medications provide a physiological advantage in appetite control and satiety signaling, but lasting results require concurrent development of health-promoting behaviors. Patients have access to ongoing medical supervision throughout their weight loss journey, with providers monitoring for potential complications and adjusting treatment protocols based on individual response patterns and emerging metabolic data.